PYXS Pyxis Oncology, Inc.
Research report · from SEC EDGAR
executive summary
Pyxis Oncology, Inc. (PYXS). Revenue is $13.9M (-14.2% y/y) at a -575% net margin. It is not yet profitable. Our health score is F (27/100). 2 red flags on file. It may need to raise cash (dilution risk).
Revenue (FY)
$13.9M
-14.2% y/y
⛔Going-concern warning
Auditor flagged substantial doubt about the company continuing for the next 12 months — a raise is usually required.
⚠Weak fundamentals
Piotroski F-Score of 2/9 — most quality checks are failing.
who's buying
Insider buys / sells
0 / 2
Cash & ST investments
$41.0M
Operating cash flow
-$63.5M
Dilution shelf
active shelf
Assembled from SEC EDGAR (XBRL, Form 4, 13F, filings), STOCK Act disclosures, and end-of-day prices — every figure is real and sourced; nothing is fabricated or predicted. Filings lag 40–90 days. Educational, not investment advice. Generated today by stocktools.ai.